Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals has signed an agreement to acquire all of the outstanding shares of Adolor for $190m.
Subscribe to our email newsletter
The entire transaction will amount to $415m.
As per the deal, Cubist will purchase all of the outstanding shares of Adolor for the upfront cash payment and a Contingent Payment Right (CPR).
The deal is expected to be complete in the fourth quarter of 2011.
Cubist Pharmaceuticals emphasizes on the research, development, and commercialization of pharmaceutical products.
Adolor focuses on discovery, development and commercialization of prescription pain and pain management products.